J&J Opens Data Vault to Yale, in ‘Unprecedented’ Transparency Move

J&J Opens Data Vault to Yale, in ‘Unprecedented’ Transparency Move.

Jan 31, 2014 at 6:40PM

Pharma companies have been feeling the heat for years from people who argue they must be more transparent with raw clinical trial data-including the good and the bad-so that independent researchers can verify their claims and learn more from failed studies that traditionally get buried.

Today, Johnson & Johnson (NYSE: JNJ) is planting a stake in the ground on the issue of transparency, and claiming it will go further in the direction of openness than other pharma company.

New Brunswick, NJ-based J&J, the diversified maker of drugs, medical devices and consumer health products, is announcing today it has struck an agreement with the Yale School of Medicine's Open Data Access Project (YODA) to open up access to all of its company-sponsored studies. Other companies have taken steps in this direction, such as GlaxoSmithKline, but the industry has mostly shied away from transparency partly over fears of violating patient privacy and giving ammunition to trial lawyers suing on behalf of patients who suffered adverse drug reactions.

What's unusual about this deal is how far J&J has been willing to go to open up its data warehouses. Instead of setting up its own committee of industry vets to evaluate the scientific merit of data requests—and suffering from a fox-watching-the-henhouse ethical problem—J&J is handing over that decision-making authority to independent, third-party experts at Yale. J&J has also said it will honor scientific data requests going as far back in time as its data are available, and it will provide richly detailed clinical study reports and patient-level data-not just summaries of the type that get published in peer-reviewed journals.

"It's unprecedented. It's an extraordinary donation to society, saying scientists around the world can have access to their clinical trial data," said Harlan Krumholz, a professor of medicine at Yale who helped craft the deal with J&J. "It honors the patients who participated in the trials and the scientists who helped design the studies. Many of these trials were never published. But now they're willing to engage in a crowdsourcing of science. They are allowing people to generate new insights."

One leading advocate for open-source biology, or pharmaceutical data transparency, was less enthused at first glance, however. Stephen Friend, a former Merck executive and now CEO of Sage Bionetworks, said he needs to see more of the details of the agreement before declaring victory for transparency activists.

"I don't think not possible to express enthusiasm, beyond a general sense, for something without first understanding the criteria by which people are going to say 'I'll agree, or not agree' to make something public,'" Friend said.

The pharmaceutical industry, as everyone who has read newspapers the past 10 years knows, has been dogged by a series of drug safety scandals and public outrage over the industry's desire to keep raw safety data hidden from independent prying eyes. Names like Vioxx and Avandia and Ketek and fen-phen are just a few of the names synonymous with this common practice of keeping data hidden, and declaring it must be that way to protect trade secrets.

As the world has become increasingly connected in the Internet age, and people have begun to see the benefits of openness (fresh scientific insights), in context with the risks (potential privacy violations and legal ammo), pharma has started to make some steps in this direction.

Joanne Waldstreicher, J&J's chief medical officer, and a prime mover inside the company for this new agreement with Yale, said the company is doing this because it wants to advance science. Krumholz raved about the company's willingness to do that, saying the company didn't refuse any request he made to do the data transparency initiative the right way. He did say the 'terms and conditions' of the data sharing agreements call for users to have a valid scientific request, and not to request data for a commercial or litigious purpose. But naturally, he said, that will be hard to stop in practice.

Waldstreicher, in an interview, added that J&J has "always believed in the transparency of our data," and has worked over the years to honor valid scientific requests. What's different here is that by handing over authority to Yale, the company hopes to be "more systematic and objective" in how it handles these requests. Yale is particularly well-suited as a partner, she said, because of its expertise in open data access, and ability to handle diversified data sets for drugs, devices, and consumer products, she said.

Waldstreicher said she recognizes there are risks in making so much data available from the company's data troves. "This is going to be a learning experience," Waldstreicher says. "We'll start it and see how it goes. If there are challenges, and constructive input, we'll incorporate those and learn along the way."

Every effort will be making to make patient-level data anonymous, Waldstreicher says. But sometimes in the case of rare diseases, with only a handful of patients in a study, it may be impossible to make patient-level data truly anonymous, she said.

Will any other pharma companies follow this lead? Krumholz said he's spoken to many other companies about similar initiatives over the years, and he's not sure. "I have talked to other companies about this approach. There's a lot of resistance or reluctance," Krumholz says. "What I do find is that when one company shows what's possible, others do follow."

The Motley Fool's Top Stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

This article originally appeared on Xconomy, along with:

Xconomy has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers